Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Vaccine|March 7, 2017
Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumoniaGertjan H J Wagenvoort, Elisabeth A M Sanders, Hester E de Melker, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2022
Target attainment and pharmacokinetics of cefotaxime in critically ill patients undergoing continuous kidney replacement therapyAndré Wieringa, Peter G J Ter Horst, Gertjan H J Wagenvoort, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 17, 2017
Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015Gertjan H J Wagenvoort, Elisabeth A M Sanders, Bart J Vlaminckx, et al.
Emerging Infectious Diseases|October 22, 2015
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the NetherlandsMirjam J Knol, Gertjan H J Wagenvoort, Elisabeth A M Sanders, et al.
Vaccine|January 19, 2016
Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the NetherlandsGertjan H J Wagenvoort, Elisabeth A M Sanders, Bart J Vlaminckx, et al.
Vaccine|December 10, 2015
Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The NetherlandsGertjan H J Wagenvoort, Mirjam J Knol, Hester E de Melker, et al.
Future Microbiology|December 18, 2015
Pneumococcal population in the era of vaccination: changes in composition and the relation to clinical outcomesKarin E Elberse, Gertjan H J Wagenvoort, Gerlinde N Pluister, et al.
Vaccine|July 3, 2017
Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The NetherlandsStefan M T Vestjens, Gertjan H J Wagenvoort, Jan C Grutters, et al.
Pageof 1